Pulmonology, Critical Care, Allergy, and Sleep Medicine
The Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at MUSC has consistently been identified as high-performing by U.S. News & World Report, meaning that it is among the top 25% of such programs in the country. The Division’s nationally renowned faculty provides expert diagnosis and management of patients with acute and chronic diseases of the chest, sleep-disordered breathing, and allergic diseases. Each year, the Division treats more than ten thousand patients from around the world and attracts two hundred applications for five fellowship positions. Our faculty provides state-of-the-art management of critically ill patients, including advanced monitoring and ventilation techniques, as well as class="st"extracorporeal membrane oxygenation (ECMO) in selected cases. The Division has a growing lung transplantation program for patients with end-stage lung disease, including those with chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension, and cystic fibrosis. The Division has a very active interventional bronchoscopy service, providing specialized diagnostic and therapeutic interventions to patients with cancer and other diseases.
The Division’s state-of-the-art eight-bed Sleep Center, designed to meet the rigorous standards of the American Academy of Sleep Medicine, focuses on the comprehensive evaluation and management of a myriad of sleep disorders, including obstructive sleep apnea, upper airway resistance syndrome, narcolepsy, insomnia, and restless leg syndrome. A multidisciplinary and comprehensive approach is taken in the evaluation of patients in collaboration with specialists in otolaryngology (ranked #27 in the nation by U.S. & News Report), neurology, and psychiatry.
Several of our faculty serve as site investigators for clinical trials in cystic fibrosis, idiopathic pulmonary fibrosis and lung cancer, providing patients the opportunity to benefit from cutting-edge research. Additional research interests of the faculty include early screening for lung cancer, outcome research in sepsis, and mechanisms of acute lung injury.
MUSC pulmonologist Gerard Silvestri, M.D., was the first n the state to offer patients with medication-refractory severe asthma a new treatment option—bronchial thermoplasty.
The MUSC Center for Cystic Fibrosis (CF), adult and pediatric programs, awarded the 2011-2012 Quality Care Award at the North American CF Conference.
Charlie Strange, M.D., an MUSC professor, treated the first patient in the United States in the RENEW study, which is evaluating the use of PneumRx Inc.'s RePneu lung volume reduction coil in patients with severe emphysema.
Lynn Schnapp, M.D., is the new Chief of the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine at the Medical University of South Carolina. In that role, she hopes to build on the strong clinical program at MUSC while expanding mentoring resources for faculty members and enhancing the research and academic profile of the Division.